Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.44 |
| ▸ | ESR1 | P03372 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27087469 | 1.00 | ESR2 (0.44) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL27255292 | 0.78 | ALOX5 (0.40) | ESR2ESR1PTGS2MEN1KMT2A | |
| SCHEMBL30500261 | 0.75 | ESR1 (0.46) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL25211145 | 0.75 | ESR1 (0.46) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL30500299 | 0.73 | ESR2 (0.42) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL25202116 | 0.73 | ESR2 (0.42) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL25195367 | 0.71 | SMN1; SMN2 (0.65) | KDM4EALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL30500265 | 0.71 | SMN1; SMN2 (0.65) | KDM4EALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL25202713 | 0.70 | MAPT (0.60) | ESR2ESR1KDM4EALDH1A1NPC1 | |
| SCHEMBL30500214 | 0.70 | MAPT (0.60) | ESR2ESR1KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208959-A1 | THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4319872-A1 | THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216627-A1 | THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208959-A1 | THIAZOLE/ISOTHIAZOLE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | ESR2 1654/4885ESR1 2070/4885KDM4E 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.